Ultragenyx's Dojolvi Ok'd In Canada For Genetic Metabolic Disorder

by Vandana Singh, Benzinga Editor

February 17, 2021 10:44 AM | 1 min read

Health Canada approves Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).
LC-FAOD are a group of rare, genetic, metabolic deficiencies caused by defects in the enzymes needed to produce energy from fatty acids.
Dojolvi is a highly purified, synthetic, 7-carbon fatty acid triglyceride specifically designed to provide medium-chain, odd-carbon fatty acids as an energy source and metabolite replacement.
The treatment received U.S. approval in July last year.
Price Action: RARE stock decreased 1.54% at $142.11 in trading session on last check Wednesday.

Posted In: Biotech News FDA General Genetic Metabolic Disorder Health Canada

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.